This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
HIV/AIDS	HIV gp120; HIV gp41	<p>Studies in human serum samples suggest broadly neutralizing antibodies (bNAbs) could help prevent HIV rebound after antiretroviral therapy. In stimulated CD4⁺ T cells from patients with HIV whose plasma viremia was well controlled on antiretroviral therapy, a panel of bNAbs against HIV gp120 or gp41 bound to virions induced from the viral reservoir and decreased viral replication compared with an inactive control IgG. In HIV patient serum incubated with CD4⁺ T cells from healthy subjects, pretreatment of the serum with each bNAbs led to decreased viral entry into healthy T cells compared with pretreatment using an inactive control IgG. Ongoing work includes optimizing combinations of bNAbs that suppress viral replication.</p> <p>SciBX 7(35); doi:10.1038/scibx.2014.1046 Published online Sept. 11, 2014</p>	Unpatented; licensing status not applicable	<p>Chun, T.-W. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Aug. 25, 2014; doi:10.1073/pnas.1414148111 Contact: Anthony S. Fauci, National Institute of Allergy and Infectious Diseases, Bethesda, Md. e-mail: afauci@niaid.nih.gov Contact: Tae-Wook Chun, same affiliation as above e-mail: twchun@nih.gov</p>